Navigation Links
RBC Life Sciences' 2008 Net Sales Increase 13 Percent as Its Nutritional Supplements and Medical Products Brands See Continued Growth

IRVING, Texas, Feb. 25 /PRNewswire-FirstCall/ -- (OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, announced today that 2008 net sales increased 13 percent year over year as the company continued its domestic and international growth.

The company reported net sales of $30.4 million for the year ended December 31, 2008, compared to $27 million during the same period in 2007. It also reported net earnings of $1.62 million, or $0.07 per diluted share, in 2008 compared to net earnings of $1.69 million, or $0.08 per diluted share, in 2007.

"In 2008, RBC Life Sciences continued the surge in growth that the company witnessed in 2007, when the firm produced record-setting earnings," said President and CEO John W. Price. "Sales generated by our international licensees grew 18 percent year over year while sales generated by our medical products brand, MPM Medical, Inc., grew 41 percent during that time. This growth is occurring at the same time that we are beginning to see good gains in our domestic, independent sales force."

Mr. Price, who was promoted to CEO last month, began laying the framework in early 2008 for increased domestic and international growth across the company's nutritional supplements and medical products brands. In addition to hiring a sales director, communications director, science and technology director and a new vice president of marketing, Mr. Price recruited a strategic-growth veteran to the board of directors.

With international sales running strongly, Mr. Price redoubled the company's focus on rebuilding the independent Associate base responsible for driving domestic sales of nutritional supplements. Since launching the first phase of this effort on November 1, more than 1,100 new Associates have joined RBC Life Sciences. The second phase of the rebuilding effort will include revising the Associate compensation system to make it one of the industry's most-rewarding commission plans.

Mr. Price said that 2008 net earnings were affected by improvements to RBC Life Sciences headquarters' facility and upgrades to its operational infrastructure.

About RBC Life SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange

                                RBC Life Sciences, Inc.
                             Summary Results of Operations
                         (in thousands, except per share data)

                                                   Years Ended December 31,
                                                     2008           2007

     Net sales                                   $  30,409     $   27,029
     Gross profit                                   15,494         14,899
     Operating profit                                2,852          2,899
     Earnings before income taxes                    2,677          2,689
     Provision for income taxes                      1,061            997
     Net earnings                                    1,616          1,692

     Earnings per share - basic                  $    0.08     $     0.08
     Earnings per share - diluted                     0.07           0.08

     Weighted average shares outstanding -
      basic                                         21,465         20,396
     Weighted average shares outstanding -
      diluted                                       22,839         22,206

                                 RBC Life Sciences, Inc.
                                Condensed Balance Sheets
                                     (in thousands)

                                                  December 31,    December 31,
                                                      2008           2007
     Cash and cash equivalents                  $     4,973     $    6,369
     Inventories                                      5,707          4,725
     Other current assets                             2,245          1,334
       Total current assets                          12,925         12,428
     Other assets                                     6,841          6,730
       Total assets                                 $19,766     $   19,158

     Liabilities and shareholders' equity
     Accounts payable and accrued liabilities   $     3,228     $    4,431
     Deferred revenue                                 4,279          4,323
     Other current liabilities                          144            136
       Total current liabilities                      7,651          8,890
     Other liabilities                                2,728          2,690
     Shareholders' equity                             9,387          7,578
       Total liabilities and shareholders'
        equity                                  $    19,766     $   19,158

SOURCE RBC Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caliper Life Sciences Fourth Quarter 2008 Financial Results Conference Call Notice
2. Breathe California of Sacramento-Emigrant Trails Fighting to Keep Hackademy Awards Name in Trademark Action Brought By Academy of Motion Picture Arts and Sciences
3. HUYA Bioscience International Announces Collaboration Agreement With the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
4. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
5. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
6. Accordent Delivers Medical Lecture Capture Platform for University of Texas Health Sciences Center
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
8. Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas
9. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
10. Introducing HEAL-WA--New Initiative Brings Evidence-Based Health Sciences Information to Health Professionals in Washington State
11. Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
Post Your Comments:
(Date:11/28/2015)... PA (PRWEB) , ... November 28, 2015 , ... Safe ... the creativity of two inventors, one from Lakewood, New Jersey and the other from ... developed the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: